Cystic Hypersecretory Hyperplasia of Breast.
Singh K, Falkenberry S, Eklund B, Quddus MR.
Int J Surg Pathol. 2018 Aug;26(5):432-433. doi: 10.1177/1066896917741979. Epub 2017 Dec 3.
Apocrine lesions of the breast.
Quinn CM, D'Arcy C, Wells C.
Virchows Arch. 2022 Jan;480(1):177-189. doi: 10.1007/s00428-021-03185-4. Epub 2021 Sep 18.
Breast Cyst.
Kowalski A, Okoye E.
2023 Sep 4. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Cystic apocrine hyperplasia is the most common finding in MRI detected breast lesions.
Ginter PS, Winant AJ, Hoda SA.
J Clin Pathol. 2014 Feb;67(2):182-6. doi: 10.1136/jclinpath-2013-201804. Epub 2013 Oct 22.
Atypical cystic hypersecretory lesions of the breast commonly harbour TP53 alterations.
Boyraz B, Sgroi DC, Iafrate AJ, Lerwill MF.
Histopathology. 2023 Dec;83(6):989-993. doi: 10.1111/his.15056. Epub 2023 Sep 28.
Breast cancer risk associated with proliferative breast disease and atypical hyperplasia.
Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, Schuyler PA, Plummer WD.
Cancer. 1993 Feb 15;71(4):1258-65. doi: 10.1002/1097-0142(19930215)71:4<1258::aid-cncr2820710415>3.0.co;2-i.
Female type cystic hyperplasia in a male breast.
McClure J, Banerjee SS, Sandilands DG.
Postgrad Med J. 1985 May;61(715):441-3. doi: 10.1136/pgmj.61.715.441.
Cystic hypersecretory hyperplasia and cystic hypersecretory duct carcinoma of the breast. Pathology, therapy, and follow-up of 39 patients.
Guerry P, Erlandson RA, Rosen PP.
Cancer. 1988 Apr 15;61(8):1611-20. doi: 10.1002/1097-0142(19880415)61:8<1611::aid-cncr2820610819>3.0.co;2-o.
Pregnancy-like hyperplasia and cystic hypersecretory changes adjacent to metaplastic carcinoma of the breast.
Kelten C, Boyaci C, Leblebici C, Trabulus DC, Nazli MA.
Indian J Pathol Microbiol. 2016 Jan-Mar;59(1):126-7. doi: 10.4103/0377-4929.178238.
Cystic hypersecretory lesions - invasive breast carcinoma-spectrum of a rare tumour.
Mitra S.
Autops Case Rep. 2023 Nov 27;13:e2023460. doi: 10.4322/acr.2023.460. eCollection 2023.
